Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a head zapper and gentle yoga ease knee pain in dementia?

NCT ID NCT07303998

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study explores whether combining a safe, low-level electrical brain stimulation (tDCS) with online chair yoga can help manage chronic knee pain in older adults with Alzheimer's or related dementias. Forty participants, along with their caregivers, will do 14 supervised sessions at home over four weeks. The goal is to see if this non-drug approach is practical and reduces pain, improves mood, and boosts quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial direct current stimulation (tDCS) and online chair yoga
What this could lead to
If it works, this could offer a safe, non-drug way to manage chronic knee pain in people with dementia, reducing reliance on risky painkillers.
What could go wrong
This is a small, early feasibility study with only 40 participants, so results may not apply widely. The combination approach is new and may not show clear benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria (participants): * Live in the community (not institutionalized). * Have a diagnosis of Alzheimer's disease and related dementias (ADRD), including Alzheimer's disease, Lewy Body Dementia, Vascular Dementia, or Multiple Etiology Dementias (MED) diagnosed by a neurologist or other healthcare provider. * Be in mild to moderate ADRD, as indicated by a Quick Dementia Rating Scale (QDRS) score between 6 and 20.5. * Score above 10 on the Montreal Cognitive Assessment (MoCA). * Experience chronic knee pain (caregiver-reported average pain in the past 3 months \> 40 out of 100). * Have no planned changes to their medication regimen or other interventions for knee pain during the trial. * Agree to participate in both transcranial direct current stimulation (tDCS) and online chair yoga (OCY). * Be able to ambulate independently with minimal assistance (e.g., using a cane or walker) for participation in OCY and the Timed Up and Go (TUG) test. - -- Be English-speaking and able to understand verbal instructions (literacy not required). * Be able to consent for themselves or identify a legally authorized representative who can provide written informed consent. * Exhibit neuropsychiatric symptoms (e.g., apathy, agitation). * Be naïve to yoga and tDCS. Exclusion Criteria (participants): * a history of brain surgery, brain tumor, head trauma, seizure/epilepsy, stroke, cancer affecting the head, or intracranial metal implantation; * systemic rheumatic disorders, including rheumatoid arthritis, systemic lupus erythematosus, or fibromyalgia; * prosthetic knee replacement or non-arthroscopic surgery to the affected knee; * compromised skin integrity on the head in the area where electrodes will be placed; * serious comorbidities that preclude participation in tDCS or OCY (e.g., heart failure \[level IV\] causing shortness of breath on exertion); * hospitalization within the preceding year for neuropsychiatric illness that would impact knee pain or interfere with study procedures; * use of another neurostimulation device (e.g., spinal cord stimulator, cardio-stimulator, or implanted cardioverter-defibrillator). Inclusion Criteria (caregivers): A caregiver is defined in this study as the person who provides care and assistance to a patient with ADRD (e.g., helping with daily activities, managing medications, ensuring safety). * Caregivers must be at least 18 years old * have provided care and assistance to the patient for at least 10 hours per week at the time of enrollment * anticipate continuing to provide care and assistance for the next 4 months (until the study ends) * be willing to receive tDCS training, administer home-based tDCS sessions, and assist the patient in attending OCY sessions * have access to a reliable Internet connec¬tion for secure videoconferencing for real-time remote supervision * English-speaking caregivers who can understand verbal instructions. Exclusion Criteria (caregivers): * alcohol/substance use disorder * inability to understand English * disability that would prevent assisting patients with ADRD from participating in tDCS and OCY (e.g., blindness, deafness) * unwillingness to provide care and assistance to patients until the study is completed. * If caregiver does not meet the inclusion/exclusion criteria, the participant will not be accepted into the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer'S disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Arizona College of Nursing

    RECRUITING

    Tucson, Arizona, 85721, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.